{"id":"efudex","_chembl":{"chemblId":"CHEMBL185","moleculeType":"Small molecule","molecularWeight":"130.08"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Efudex®","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:40:24.676774+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T06:40:40.005494+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:40:30.785835+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Efudex®","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:40:31.248464+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: RNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:40:32.290293+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL185/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:40:31.956685+00:00"}},"_dailymed":{"setId":"35de1c1c-bef5-46c5-b6f8-ea032147411c","title":"EFUDEX (FLUOROURACIL) SOLUTION EFUDEX (FLUOROURACIL) CREAM [BAUSCH HEALTH US, LLC]"},"aiSummary":"Efudex®, marketed by Sol-Gel Technologies, Ltd., is a well-established topical treatment in the dermatology segment. The drug's key composition patent is set to expire in 2028, providing a clear period of market exclusivity. The primary risk lies in potential generic competition following the patent expiry, which could erode market share and revenue.","_scrapedAt":"2026-03-28T01:10:38.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:40:40.005620+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT06948448","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2025-11-18","conditions":"Colorectal Cancer","enrollment":144},{"nctId":"NCT05152147","phase":"PHASE3","title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2021-12-02","conditions":"Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":920},{"nctId":"NCT07043400","phase":"PHASE3","title":"A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-08-27","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":351},{"nctId":"NCT07044362","phase":"NA","title":"Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-06-30","conditions":"Colorectal Cancer, Liver Metastases, Liver Cancer","enrollment":100},{"nctId":"NCT06731478","phase":"PHASE3","title":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-02-27","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":726},{"nctId":"NCT06469944","phase":"PHASE1, PHASE2","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-20","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":160},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT06780111","phase":"PHASE1, PHASE2","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":298},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":770},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT04757363","phase":"PHASE2","title":"A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-02-11","conditions":"Esophagogastric Cancer, HER2-Negative","enrollment":39},{"nctId":"NCT04929223","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":"Metastatic Colorectal Cancer","enrollment":542},{"nctId":"NCT06057038","phase":"PHASE1","title":"A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2023-11-24","conditions":"Malignant Solid Tumor","enrollment":42},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT03675737","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-11-08","conditions":"Stomach Neoplasms","enrollment":1579},{"nctId":"NCT03785873","phase":"PHASE1, PHASE2","title":"Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2019-05-22","conditions":"Biliary Tract Cancer","enrollment":34},{"nctId":"NCT05067283","phase":"PHASE1","title":"A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-12-17","conditions":"Advanced Solid Tumors","enrollment":830},{"nctId":"NCT05062317","phase":"PHASE2","title":"ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-26","conditions":"Liver Metastases","enrollment":120},{"nctId":"NCT07030283","phase":"PHASE1","title":"Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-12-31","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":10},{"nctId":"NCT06428409","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-20","conditions":"Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer","enrollment":220},{"nctId":"NCT05945823","phase":"PHASE2","title":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-07-13","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer","enrollment":53},{"nctId":"NCT04949256","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-07-28","conditions":"Metastatic Esophageal Squamous Cell Carcinoma","enrollment":864},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT04662710","phase":"PHASE3","title":"Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-30","conditions":"Advanced/Metastatic Gastroesophageal Adenocarcinoma","enrollment":895},{"nctId":"NCT01358877","phase":"PHASE3","title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-08","conditions":"Breast Cancer","enrollment":4804},{"nctId":"NCT04854499","phase":"PHASE2","title":"Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-09-07","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":193},{"nctId":"NCT02967289","phase":"PHASE3","title":"IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2017-03-27","conditions":"Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2)","enrollment":792},{"nctId":"NCT04656041","phase":"PHASE2","title":"Folfox+Irinotecan+Chemort In Esophageal Cancer","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-06-29","conditions":"Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer","enrollment":40},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT05212012","phase":"PHASE1, PHASE2","title":"D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AIO-Studien-gGmbH","startDate":"2022-02-17","conditions":"Chemo-refractory Colorectal Carcinoma","enrollment":11},{"nctId":"NCT04595266","phase":"PHASE2","title":"Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2021-06-29","conditions":"Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer","enrollment":48},{"nctId":"NCT02008656","phase":"PHASE2","title":"Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-11","conditions":"Rectal Cancer","enrollment":358},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT04675333","phase":"PHASE2","title":"Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ALX Oncology Inc.","startDate":"2021-05-10","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":172},{"nctId":"NCT02358031","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-03-19","conditions":"Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer","enrollment":882},{"nctId":"NCT04901741","phase":"PHASE2","title":"Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"TME Pharma AG","startDate":"2026-01","conditions":"Metastatic Pancreatic Cancer","enrollment":60},{"nctId":"NCT07026123","phase":"","title":"A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-07-01","conditions":"Advanced Pancreatic Cancer","enrollment":40},{"nctId":"NCT04082364","phase":"PHASE2, PHASE3","title":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","status":"COMPLETED","sponsor":"MacroGenics","startDate":"2019-09-30","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer","enrollment":82},{"nctId":"NCT02720068","phase":"PHASE1","title":"Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-02","conditions":"Neoplasms","enrollment":481},{"nctId":"NCT04393298","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2020-07-09","conditions":"Advanced Solid Tumors","enrollment":93},{"nctId":"NCT04276857","phase":"NA","title":"Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"University of Saskatchewan","startDate":"2025-05-01","conditions":"Locally Advanced Pancreatic Cancer, Irreversible Electroporation","enrollment":27},{"nctId":"NCT05383352","phase":"PHASE1","title":"A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas","status":"COMPLETED","sponsor":"Ipsen","startDate":"2022-05-30","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":177},{"nctId":"NCT05004350","phase":"PHASE2","title":"A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2021-09-14","conditions":"BRAF V600E, Metastatic Colorectal Cancer","enrollment":107},{"nctId":"NCT04256707","phase":"PHASE1, PHASE2","title":"Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-01-14","conditions":"Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors","enrollment":126},{"nctId":"NCT03829410","phase":"PHASE1, PHASE2","title":"Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation","status":"COMPLETED","sponsor":"Cardiff Oncology","startDate":"2019-06-24","conditions":"Metastatic Colorectal Cancer, KRAS Gene Mutation","enrollment":68},{"nctId":"NCT03197584","phase":"PHASE1, PHASE2","title":"QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Ovarian Cancer","enrollment":""},{"nctId":"NCT03777657","phase":"PHASE3","title":"Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-13","conditions":"Gastric, or Gastroesophageal Junction Adenocarcinoma","enrollment":997},{"nctId":"NCT03563157","phase":"PHASE1, PHASE2","title":"QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-09-28","conditions":"Colorectal Cancer Metastatic, mCRC","enrollment":2},{"nctId":"NCT04241185","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-19","conditions":"Urinary Bladder Neoplasms","enrollment":520},{"nctId":"NCT02009449","phase":"PHASE1","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11-15","conditions":"Melanoma, Prostate Cancer, Ovarian Cancer","enrollment":353},{"nctId":"NCT04210115","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)","enrollment":703},{"nctId":"NCT06688240","phase":"","title":"A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)","status":"NOT_YET_RECRUITING","sponsor":"Servier (Tianjin) Pharmaceutical Co. LTD.","startDate":"2024-11","conditions":"Metastatic Pancreatic Cancer","enrollment":120},{"nctId":"NCT04456699","phase":"PHASE3","title":"Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-19","conditions":"Metastatic Colorectal Cancer","enrollment":335},{"nctId":"NCT02563002","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-30","conditions":"Colorectal Carcinoma","enrollment":307},{"nctId":"NCT02826486","phase":"PHASE2","title":"Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2016-09","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":80},{"nctId":"NCT06110598","phase":"PHASE2","title":"CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-12-01","conditions":"Pancreas Cancer, Pancreas Adenocarcinoma","enrollment":""},{"nctId":"NCT03336216","phase":"PHASE2","title":"A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-12-18","conditions":"Advanced Pancreatic Cancer","enrollment":205},{"nctId":"NCT06274320","phase":"NA","title":"Effect of Lipikar Urea 30% Before Actinic Keratoses Treatment","status":"RECRUITING","sponsor":"Cosmetique Active International","startDate":"2024-04-05","conditions":"Actinic Keratoses","enrollment":100},{"nctId":"NCT02735239","phase":"PHASE1, PHASE2","title":"Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2016-06-24","conditions":"Esophageal Cancer","enrollment":73},{"nctId":"NCT01679054","phase":"","title":"Cost-minimization Analysis of Gastric Cancer Treatments in Hong Kong","status":"COMPLETED","sponsor":"Vivian Wing Yan Lee","startDate":"2011-10","conditions":"Gastric Cancer","enrollment":58},{"nctId":"NCT03549494","phase":"PHASE2","title":"Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction","status":"COMPLETED","sponsor":"Catalysis SL","startDate":"2018-10-25","conditions":"Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm","enrollment":45},{"nctId":"NCT03283761","phase":"PHASE2","title":"FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Al B. Benson, III, MD","startDate":"2017-09-21","conditions":"Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer","enrollment":39},{"nctId":"NCT06210360","phase":"PHASE2","title":"Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2024-02-01","conditions":"Pancreatic Cancer","enrollment":134},{"nctId":"NCT03618758","phase":"PHASE1, PHASE2","title":"Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2018-12-24","conditions":"Gastric Cancer Stage IV, Peritoneal Carcinomatosis, Intraperitoneal Paclitaxel","enrollment":35},{"nctId":"NCT03914170","phase":"","title":"Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2017-04-01","conditions":"Colorectal Cancer","enrollment":70},{"nctId":"NCT01468623","phase":"PHASE4","title":"Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6","status":"TERMINATED","sponsor":"Myriad Genetic Laboratories, Inc.","startDate":"2011-09","conditions":"Colorectal Cancer, Metastatic","enrollment":51},{"nctId":"NCT05513924","phase":"PHASE2, PHASE3","title":"Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.","status":"COMPLETED","sponsor":"South Valley University","startDate":"2022-03-15","conditions":"Vitiligo","enrollment":40},{"nctId":"NCT00003298","phase":"PHASE2","title":"Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"1999-06-01","conditions":"Gastric Cancer","enrollment":39},{"nctId":"NCT01991873","phase":"PHASE2","title":"Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-04","conditions":"Metastatic Colorectal Cancer","enrollment":387},{"nctId":"NCT01420874","phase":"PHASE1","title":"Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2011-08-17","conditions":"Colorectal Cancer, Cancer of Pancreas, Pancreatic Neoplasm","enrollment":15},{"nctId":"NCT02578732","phase":"PHASE2","title":"FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial","status":"COMPLETED","sponsor":"Brown University","startDate":"2016-07-12","conditions":"Locally Advanced Pancreatic Cancer, Pancreatic Cancer","enrollment":28},{"nctId":"NCT04088604","phase":"PHASE1","title":"Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2019-02-15","conditions":"Advanced Solid Tumor","enrollment":38},{"nctId":"NCT02494583","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-31","conditions":"Gastric Adenocarcinoma","enrollment":763},{"nctId":"NCT03712397","phase":"PHASE2","title":"Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-12-24","conditions":"Head & Neck Cancer","enrollment":59},{"nctId":"NCT03391934","phase":"PHASE3","title":"Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Cinnagen","startDate":"2018-01-20","conditions":"Metastatic Colorectal Cancer","enrollment":234},{"nctId":"NCT05797883","phase":"PHASE2","title":"FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2022-08-01","conditions":"Unresectable or Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT00364013","phase":"PHASE3","title":"PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-08-01","conditions":"Metastatic Colorectal Cancer","enrollment":1183},{"nctId":"NCT01779050","phase":"PHASE2","title":"Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2013-12-19","conditions":"Breast Neoplasms","enrollment":7},{"nctId":"NCT00467142","phase":"PHASE2","title":"Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2007-01-23","conditions":"Colorectal Cancer","enrollment":62},{"nctId":"NCT00339183","phase":"PHASE3","title":"Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-06-30","conditions":"Metastatic Colorectal Cancer","enrollment":1186},{"nctId":"NCT02335411","phase":"PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-03","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":318},{"nctId":"NCT02080221","phase":"PHASE2","title":"BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial","status":"COMPLETED","sponsor":"Brown University","startDate":"2014-08","conditions":"Metastatic Pancreatic Cancer","enrollment":50},{"nctId":"NCT02143219","phase":"PHASE2","title":"Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2014-07-31","conditions":"Pancreatic Metastatic Cancer, Toxicity","enrollment":72},{"nctId":"NCT02661971","phase":"PHASE2, PHASE3","title":"FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2016-06","conditions":"Stomach Cancer, Gastroesophageal Junction Cancer","enrollment":180},{"nctId":"NCT05378867","phase":"PHASE3","title":"A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC","status":"UNKNOWN","sponsor":"Zhejiang Teruisi Pharmaceutical Inc.","startDate":"2022-08-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":126},{"nctId":"NCT03904381","phase":"PHASE4","title":"Efficacy and Safety of XEN® Gel Stent and Post-operative Management in Patients With Open Angle Glaucoma","status":"UNKNOWN","sponsor":"Wroclaw Medical University","startDate":"2016-01-01","conditions":"Open-angle Glaucoma","enrollment":100},{"nctId":"NCT01525329","phase":"PHASE3","title":"Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2011-09","conditions":"Actinic Keratosis, Organ or Tissue Transplant; Complications","enrollment":18},{"nctId":"NCT05095064","phase":"","title":"Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan","status":"UNKNOWN","sponsor":"University Hospital, Antwerp","startDate":"2021-09-27","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT01526135","phase":"PHASE3","title":"Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2012-04-16","conditions":"Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)","enrollment":493},{"nctId":"NCT04859582","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-11-08","conditions":"Stomach Neoplasms","enrollment":""},{"nctId":"NCT02052960","phase":"PHASE2","title":"CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"Glycotope GmbH","startDate":"2014-02","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":240},{"nctId":"NCT03446872","phase":"","title":"Post Marketing Surveillance Study for ONIVYDE® in South Korea","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2018-03-08","conditions":"Metastatic Pancreatic Cancer","enrollment":94},{"nctId":"NCT01442935","phase":"PHASE2","title":"Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2011-02","conditions":"Colorectal Cancer","enrollment":256},{"nctId":"NCT03286738","phase":"","title":"Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Joong Bae Ahn","startDate":"2015-11","conditions":"Metastatic Colorectal Cancer","enrollment":1800},{"nctId":"NCT02468557","phase":"PHASE1","title":"Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-07-30","conditions":"Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma","enrollment":16},{"nctId":"NCT03563170","phase":"PHASE1, PHASE2","title":"QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-25","conditions":"Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent","enrollment":""},{"nctId":"NCT02641691","phase":"PHASE2","title":"Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-05-27","conditions":"Cancer of Rectum, Cancer of the Rectum, Neoplasm, Rectum","enrollment":20},{"nctId":"NCT03703063","phase":"PHASE1","title":"Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer","status":"UNKNOWN","sponsor":"Benaroya Research Institute","startDate":"2018-09-17","conditions":"Pancreatic Adenocarcinoma","enrollment":30},{"nctId":"NCT03288987","phase":"PHASE3","title":"Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AryoGen Pharmed Co.","startDate":"2016-10-04","conditions":"Metastatic Colorectal Cancer","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL185"},"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Efudex®","genericName":"Efudex®","companyName":"Sol-Gel Technologies, Ltd.","companyId":"sol-gel-technologies-ltd","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:40:40.005620+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}